

Product Information

Anti-Cullin-2 (N-terminal) produced in rabbit, affinity isolated antibody

Product Number **SAB4200207**

Product Description

Anti-Cullin-2 is developed in rabbit using as the immunogen a synthetic peptide corresponding to a sequence at the N-terminal of human cullin-2 (GeneID 8453), conjugated to KLH. The corresponding sequence is identical in rat and mouse cullin-2. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-Cullin-2 specifically recognizes human cullin-2. The antibody may be used in various immunochemical techniques including immunoblotting (~87 kDa). Detection of the cullin-2 band by immunoblotting is specifically inhibited by the cullin-2 immunizing peptide.

Cullin-2 (also known as CUL2) is a member of the cullin family of E3 ubiquitin-protein ligases.¹ Cullins function as scaffold proteins that assemble ubiquitin ligase complexes, responsible for targeting proteins for ubiquitin-dependent degradation by the proteasome. Cullin-2 is a component of the ElonginB/C-CUL2-Rbx1-Von Hippel Lindau (VHL) VBC complex that plays an essential role in the ubiquitin-dependent degradation of the hypoxia inducible transcription factors HIF1 α and HIF2 α (HIF α).^{2,3} HIF α positively regulates VEGF and other hypoxia-inducible genes, that in turn regulate vasculogenesis. Hypoxic activation of gene expression results in part from increases in the cellular levels of HIF α that are rapidly ubiquitinated and degraded under normoxic conditions. VHL recognizes hydroxylated HIF α , and recruits the CUL2 associating complex leading to ubiquitination of HIF α .^{4,5} RNAi-mediated knockdown of the CUL2-Rbx1 has been shown to inhibit the VHL-mediated degradation of HIF2 α , indicating that CUL2 and Rbx1 are positively involved in the HIF α protein stabilization.⁵ Nedd8 has been shown to conjugate to CUL2 in a process that requires the CUL2-VHL-Elongin B/C complex.⁶ Cancer-causing mutations of VHL can prevent assembly with HIF α and core components of the E3 ubiquitin ligase complex, resulting in constitutive activation of HIF α targets.⁷

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Antibody concentration: ~1.0 mg/mL

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots at –20 °C. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: a working antibody concentration of 1-2 μ g/mL is recommended using extracts of HEK-293T cells overexpressing human cullin-2.

Note: In order to obtain best results in various techniques and preparations, it is recommended to determine optimal working dilutions by titration.

References

1. Petroski, M.D., and Deshaies, R.J., *Nat. Rev. Mol. Cell Biol.*, **6**, 9-20 (2005).
2. Michel, J.J., and Xiong, Y., *Cell Growth Different.*, **9**, 435-449 (1998).
3. Pause, A., et al., *Proc. Natl. Acad. Sci. USA*, **94**, 2156-2161 (1997).
4. Kamura, T., et al., *Proc. Natl. Acad. Sci. USA*, **97**, 10430-10435 (2000).
5. Kamura, T., et al., *Genes Dev.*, **18**, 3055-3065 (2004).
6. Wada, H., et al., *J. Biol. Chem.*, **274**, 36025-36029 (1999).
7. Khacho, M., et al., *Mol. Cell. Biol.*, **28**, 302-314 (2008).

VS,ER,TD,KAA,PHC,MAM 07/19-1